Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

Presentation TCT 2024

Overview of Latest Clinical Evidence

Presenter: David Erlinge

October 30, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

Presenter: David Erlinge

October 28, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Presenter: David Erlinge

October 28, 2024

Presentation TCT 2023

Are Progression/Regression Studies “Good Enough” Surrogates for Rcts With Clinical Endpoints?

Presenter: David Erlinge

October 24, 2023

Presentation TCT 2023

Dynamx Bioadaptor Stent Technology

Presenter: David Erlinge

October 24, 2023

Presentation TCT 2021

What Plaque Characteristics Cause Future Events: Plaque Burden, Lipid, Ischemia, or Other?

Presenter: David Erlinge

November 06, 2021

Presentation TCT 2020

It’s All About the Plaque – Plaque Burden and Morphology Are the Most Important Predictors!

Presenter: David Erlinge

October 16, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

Presentation TCT 2019

Case #1 Resolution: How Did We Treat This Patient? What Might We Have Done Differently?

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

Case #1 Introduction: PCI in a Patient With ACS

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2019

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

Presenter: David Erlinge

September 27, 2019

Presentation TCT 2018

OAC ALONE: Summary and Clinical Implications

Presenter: John A. Bittl, David Erlinge, Takashi Kubo, Yukiko Nakano

September 24, 2018

Presentation TCT 2018

LRP: Summary and Clinical Implications

Presenter: John A. Bittl, David Erlinge, Takashi Kubo, Ron Waksman

September 24, 2018

Presentation TCT 2018

ULTIMATE: Summary and Clinical Implications

Presenter: John A. Bittl, David Erlinge, Takashi Kubo, Junjie Zhang

September 24, 2018

Presentation TCT 2017

Novel Invasive Diagnostics II: NIRS-Based

Presenter: Ik-Kyung Jang, Yoshinobu Onuma, David Erlinge

November 01, 2017

Presentation TCT 2017

Prospects for Hypothermia to Reduce Infarct Size

Presenter: Bernard J. Gersh, Michel Ovize, David Erlinge

October 31, 2017

Presentation TCT 2017

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

Presenter: Thomas F. Luscher, David Erlinge

October 31, 2017

Presentation TCT 2017

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Presenter: Michael S. Lee, Dirk Sibbing, David Erlinge

October 30, 2017

Presentation TCT 2016

NIRS Detection of Vulnerable Plaque: The Story Is Intensifying

Presenter: John A. Ambrose, Peter H. Stone, David Erlinge

November 01, 2016

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Overview of Latest Clinical Evidence

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Are Progression/Regression Studies “Good Enough” Surrogates for Rcts With Clinical Endpoints?

Dynamx Bioadaptor Stent Technology

What Plaque Characteristics Cause Future Events: Plaque Burden, Lipid, Ischemia, or Other?

It’s All About the Plaque – Plaque Burden and Morphology Are the Most Important Predictors!

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Case #1 Resolution: How Did We Treat This Patient? What Might We Have Done Differently?

Case #1 Introduction: PCI in a Patient With ACS

Detection of Vulnerable Patients by NIRS (PROSPECT II) and Treatment (PROSPECT ABSORB) Rationale and Update

OAC ALONE: Summary and Clinical Implications

LRP: Summary and Clinical Implications

ULTIMATE: Summary and Clinical Implications

Novel Invasive Diagnostics II: NIRS-Based

Prospects for Hypothermia to Reduce Infarct Size

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

NIRS Detection of Vulnerable Plaque: The Story Is Intensifying

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content